Cargando…
Mesenchymal Stem Cells Do Not Prevent Antibody Responses against Human α-L-Iduronidase when Used to Treat Mucopolysaccharidosis Type I
Mucopolysaccharidosis type I (MPSI) is an autosomal recessive disease that leads to systemic lysosomal storage, which is caused by the absence of α-L-iduronidase (IDUA). Enzyme replacement therapy is recognized as the best therapeutic option for MPSI; however, high titers of anti-IDUA antibody have...
Autores principales: | Martin, Priscila Keiko Matsumoto, Stilhano, Roberta Sessa, Samoto, Vivian Yochiko, Takiya, Christina Maeda, Peres, Giovani Bravin, da Silva Michelacci, Yara Maria Correa, da Silva, Flavia Helena, Pereira, Vanessa Gonçalves, D'Almeida, Vânia, Marques, Fabio Luiz Navarro, Otake, Andreia Hanada, Chammas, Roger, Han, Sang Won |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958533/ https://www.ncbi.nlm.nih.gov/pubmed/24642723 http://dx.doi.org/10.1371/journal.pone.0092420 |
Ejemplares similares
-
α-L-iduronidase therapy for mucopolysaccharidosis type I
por: Tolar, Jakub, et al.
Publicado: (2008) -
Treatment of Mouse Limb Ischemia with an Integrative Hypoxia-Responsive Vector Expressing the Vascular Endothelial Growth Factor Gene
por: Yasumura, Eduardo Gallatti, et al.
Publicado: (2012) -
Insights into Mucopolysaccharidosis I from the structure and action of α-L-Iduronidase
por: Bie, Haiying, et al.
Publicado: (2013) -
Reduction in skeletal muscle fibrosis of spontaneously hypertensive rats after laceration by microRNA targeting angiotensin II receptor
por: Stilhano, Roberta Sessa, et al.
Publicado: (2017) -
Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy
por: Li, Ying, et al.
Publicado: (2022)